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While we must applaud industry and the Recombinant
Human Protein C Worldwide Evaluation in Severe Sepsis
(PROWESS) investigators [1] for the tremendous effort and
time expended in their multicentre, international study, caution
needs to be exercised before deciding to make the
intervention of activated protein C (APC) a standard of
treatment [2].
We, like many others, have chosen to introduce APC into our
practice in the treatment of severe sepsis, despite having an
awareness of the progress of associated controversies [3-5].
By choosing to change our practice we may have exposed
patients to occult harm or to benefit. Alternatively, patient
outcome may have remained unchanged but time, money and
clinical effort have been expended (and wasted) in the
necessary activities to affect the change. These activities are
a significant burden on the multidisciplinary team that carry
out intensive therapy, and their effects should not be
underestimated.
What impels us to change, then? Why do we not have more
patience and either wait for, agitate or participate in the need
for more data? Perhaps we feel a desire to demonstrate that
we are up to date, that we are dynamic and that we can
implement change quickly and effectively locally? We may
assume that this is what colleagues as well as the public
expect of us. Guidelines from ‘learned bodies’ [6] may also
influence us. In a world that is apparently ‘moving forward’
rapidly, we do not want to feel that we are being left behind,
unchanging and old-fashioned. We need to belong to the
group that is dynamic and contemporary.
Having become part of our practice, we now feel ambivalent
to the prescription of APC. Notwithstanding the efficacy
debate, the resource implications for the prescription of
recombinant therapies are considerable. The question of
global equitable availability is an additional issue that receives
scant attention. Some days we prescribe the intervention,
worrying about the possible side effects and resource
implications. Other days we may defend our right not to
prescribe them, concerned that we are swimming against the
dominant tide of contemporary practice. We agree whole-
heatedly with the comments of Friedrich and colleagues in a
recent issue of Critical Care [2] that we need further new
data regarding APC to clarify its treatment effect in sepsis.
Smith and Roberts [7] in their recently published seminal
paper give clear contemporary guidance on conducting and
publishing clinical trials. They state that a single randomised
clinical trial needs to be evaluated in the context of all the
information available, and thus needs to be understood in the
context of a systematic review. If there is uncertainty despite
this, and if the research question posed is deemed important,
a further trial is necessary. Is now the time for national
academic groups to build on the industry-sponsored
PROWESS study and to coordinate and design a further
randomised clinical trial – a study that is independent and
addresses the issue of the treatment effect of APC in sepsis?
We think so. We should also learn from this evolving narrative
the lesson that patience remains a virtue and change should
not be undertaken lightly.
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